clinical phase Ib/II studies

Isofol Medical AB (publ) is a publicly listed clinical-phase biotechnology company developing the drug candidate arfolitixorin, which aims to increase the efficacy of standard treatments for patients with severe forms of cancer, with an initial focus on metastatic colorectal cancer. Its shares are traded on Nasdaq Stockholm.

Read more

clinical drug developmentpreclinical research